Cheems Token (CHEEMS) posted a 9.4% gain in the past 24 hours, climbing to $0.00000054 with $2.18 million in trading volume. However, our analysis reveals the memeCheems Token (CHEEMS) posted a 9.4% gain in the past 24 hours, climbing to $0.00000054 with $2.18 million in trading volume. However, our analysis reveals the meme

Cheems Token Surges 9.4% While Trading 75% Below ATH: Market Analysis

For feedback or concerns regarding this content, please contact us at [email protected]

Cheems Token (CHEEMS) has captured trader attention with a 9.4% price surge in the past 24 hours, yet our data analysis reveals a more complex narrative beneath the headline numbers. Trading at $0.00000054 as of March 3, 2026, the meme token has generated $2.18 million in daily volume—but remains deeply underwater from its March 2025 peak, trading 75.15% below its all-time high of $0.00000216.

What makes this rally particularly noteworthy isn’t the percentage gain itself, but rather the timing and volume dynamics. The token’s 7-day performance shows a more robust 23.13% increase, suggesting this isn’t merely a flash pump but potentially the beginning of a sustained reversal pattern. However, the 30-day chart paints a sobering picture with a -9.44% decline, indicating persistent selling pressure over the medium term.

Volume Analysis Reveals Concerning Liquidity Patterns

We observe that CHEEMS’ current 24-hour trading volume of $2.18 million represents approximately 1.98% of its $109.9 million market cap—a ratio that falls below healthy liquidity thresholds for tokens of this size. Typically, we look for volume-to-market-cap ratios above 5% to indicate genuine market interest rather than thin, manipulable trading conditions.

The market cap itself presents an interesting data point: at $109.9 million with a rank of #250 on CoinGecko, Cheems Token occupies an awkward middle ground. It’s too large to qualify as a micro-cap with explosive potential, yet too small and too far from its ATH to attract serious institutional attention. This positioning often creates what we call the “valley of disinterest” where tokens struggle to generate sustained momentum.

The token’s circulating supply of 203.67 trillion tokens against a maximum supply of 219.78 trillion indicates 92.68% of tokens are already in circulation. This high circulation rate reduces future dilution risk but also means there’s limited scarcity value to drive price appreciation through supply constraints alone.

Price Action Context: Recovery or Dead Cat Bounce?

To properly contextualize today’s 9.4% move, we must examine CHEEMS’ historical price trajectory. The token hit its all-time low of $0.000000005725 on September 4, 2023, meaning current prices represent a 9,280% gain from that bottom—an impressive recovery on paper. However, this massive percentage increase is somewhat misleading given the token’s micro-price denomination.

More relevant is the March 25, 2025 all-time high, achieved during the broader meme coin mania that swept markets in early 2025. Since that peak nearly one year ago, CHEEMS has shed three-quarters of its value despite periodic rallies like today’s. This price action mirrors the broader pattern we’ve observed across meme token markets: explosive rallies followed by grinding, multi-month declines that erode most gains.

The 24-hour price range of $0.000000493729 to $0.000000546222 shows approximately 10.6% intraday volatility—high enough to attract day traders but not extreme by meme token standards. This moderate volatility suggests some level of price discovery is occurring rather than pure speculative gambling.

Market Structure and Comparative Analysis

When we compare CHEEMS to other meme tokens in the #200-300 market cap ranking range, several patterns emerge. The token’s volume-to-market-cap ratio, while low at 1.98%, actually exceeds many similarly-ranked meme coins that struggle to maintain 1% ratios. This suggests CHEEMS retains a core trading community, albeit a small one.

The fully diluted valuation (FDV) matches the market cap at $109.9 million, which is actually a positive signal—it indicates minimal overhang from locked or vesting tokens that could create future sell pressure. Many meme tokens trade at significant discounts to their FDV due to concerns about future unlocks, so CHEEMS’ 1:1 ratio eliminates this particular risk factor.

However, we must note the concerning absence of ROI data in the token’s profile. While this may simply reflect data limitations, it prevents us from analyzing investor returns from initial distribution periods—information that would help assess long-term holder conviction.

Technical Outlook and Risk Considerations

From a technical perspective, the 23.13% weekly gain suggests CHEEMS may be forming a higher low pattern after months of decline. If the token can hold above the $0.00000050 level (roughly its 24-hour low), it would establish a base for potential further recovery. However, resistance will likely prove formidable at the $0.00000060 level, which represents a psychological barrier and approximately 11% above current prices.

The primary risk factor we identify is the token’s distance from its ATH. Tokens trading 70%+ below previous peaks often face intense selling pressure from holders waiting to exit at breakeven or reduced losses. This creates a “supply ceiling” that can cap rallies. CHEEMS would need to rally 300%+ just to reach its previous high—a scenario that requires either sustained retail interest or a broader meme coin market revival.

Additionally, the 30-day negative performance of -9.44% indicates the monthly trend remains bearish despite short-term gains. We view this as a cautionary signal suggesting today’s rally may face resistance from longer-term downtrends.

Actionable Takeaways for Market Participants

For traders considering CHEEMS positions, our analysis suggests several key considerations. First, the 9.4% daily gain and 23.13% weekly performance indicate short-term momentum, but position sizing should account for the token’s 75% drawdown from ATH and low liquidity. We would recommend risk management protocols that limit exposure to no more than 1-2% of portfolio value for speculative meme token positions.

Second, volume patterns warrant close monitoring. If daily volume can sustainably exceed $5 million (approximately 4.5% of market cap), it would signal genuine accumulation rather than thin market manipulation. Conversely, volume declining below $1 million would suggest the rally is losing steam.

Third, broader market correlation must be considered. Meme tokens typically exhibit high beta to Bitcoin and major altcoins. If broader crypto markets face headwinds in March 2026, CHEEMS’ independent momentum will likely prove insufficient to sustain gains. Conversely, a return to risk-on sentiment across crypto could provide tailwinds for a more substantial recovery.

Finally, we emphasize that meme tokens like CHEEMS carry inherently high risk profiles with 70-90% drawdowns being common rather than exceptional. The token’s 9,280% gain from its all-time low demonstrates both the explosive upside and devastating downside these assets can experience. Any participation should be approached with appropriate skepticism and never with capital needed for essential purposes.

Market Opportunity
Cheems Logo
Cheems Price(CHEEMS)
$0.0000004715
$0.0000004715$0.0000004715
-2.90%
USD
Cheems (CHEEMS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09